LSD Microdosing Trial Shows Placebo Outperforms Psychedelic for Depression

A Phase 2B clinical trial investigating LSD microdosing for major depressive disorder found that a placebo regimen yielded superior outcomes compared to the active substance. The study, conducted by MindBio Therapeutics, utilized caffeine as an active placebo over an eight-week period. These top-line results challenge long-held anecdotal claims regarding the efficacy of sub-perceptual psychedelic dosing for mood disorders.